Lipide: Diagnostik und Therapie bei Diabetes mellitus Typ 2
- 19 December 2012
- journal article
- abstracts
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 124 (S2) , 28-30
Abstract
Hyper- and Dyslipidemia contribute to cardiovascular morbidity and mortality in diabetic patients. Pharmacological therapy with statins has convincingly shown to reduce cardiovascular risk in diabetic patients. The present article represents the recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in diabetic patients according to current scientific evidence. Hyper- und Dyslipidämie tragen zur kardiovaskulären Morbidität und Mortalität diabetischer Patienten bei. Überzeugende Daten zeigen, dass durch die medikamentöse Therapie mit Statinen das kardiovaskuläre Risiko von Diabetikern senken kann. Der vorliegende Artikel stellt die Behandlungsvorschläge der österreichischen Diabetesgesellschaft zum Einsatz lipidsenkender Medikamente dar.Keywords
This publication has 7 references indexed in Scilit:
- The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trialsThe Lancet, 2012
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisThe Lancet, 2008
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialThe Lancet, 2005
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein CholesterolNew England Journal of Medicine, 1999